This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

12 Bargain Stocks With Insider Support

Stocks in this article: WENGEOYAMRSOPKTASR

Opko Health

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

A great deal of (digital) ink has been spilled by insider-focused analysts trying to determine what Dr. Phil Frost is up to. He's chairman of Opko Health (OPK) and has been buying large sums of stock almost every month for more than a year.

Frost sold Ivax Pharmaceuticals to Teva Pharmaceuticals (TEVA) for $7.4 billion back in 2006. Ivax had built an impressive roster of top-selling generic drugs, and it was pretty clear why Teva would pay such a stiff price tag.

>>Health Care Stocks Bought and Sold by Hedge Funds

Opko's story isn't quite so clear-cut. The company is casting a wide net, targeting vaccines, diagnostic tests, treatments for infectious diseases, asthma, cancer, and on the list goes. Yet this is a company with just $40 million in annual sales, steady operating losses, and minimal communication with the investment community. The fact that it is already valued at $1.4 billion means that Dr. Frost is either sitting on a blockbuster of a company, or he is the most foolish insider buyer ever.

More than likely, he's on to something special. He's no fool. So investors are left to have blind faith in him.

At least the stock is now below levels of recent insider buying, providing safety. You can bet Dr. Frost will be buying stock next week, next month and next quarter, if history is any guide.

5 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs